Biodesix, Inc. Common Stock (BDSX) is a publicly traded Healthcare sector company. As of May 21, 2026, BDSX trades at $14.37 with a market cap of $144.05M and a P/E ratio of -3.06. BDSX moved +2.33% today. Year to date, BDSX is +130.66%; over the trailing twelve months it is +165.32%. Its 52-week range spans $3.44 to $36.00. Analyst consensus is strong buy with an average price target of $30.67. Rallies surfaces BDSX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Biodesix to Present Real-World Clinical and Economic Nodify Lung Data at ATS May 15–20: Biodesix will present real-world clinical and healthcare economic data on its Nodify Lung testing at the American Thoracic Society Annual Meeting, May 15–20, including an oral presentation on May 17 and four poster sessions on May 18–19. The studies involve risk stratification programs in academic and community hospitals.
| Metric | Value |
|---|---|
| Price | $14.37 |
| Market Cap | $144.05M |
| P/E Ratio | -3.06 |
| EPS | $-4.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $36.00 |
| 52-Week Low | $3.44 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $88.50M |
| Net Income | $-35.27M |
| Gross Margin | 0.00% |
5 analysts cover BDSX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.67.